nexien biopharma, a pharmaceutical company, engages in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways to address a range of medical conditions and disorders. the company was formerly known as intiva biopharma inc. and changed its name to nexien biopharma, inc. in september 2018. nexien biopharma, inc. is based in glendale, colorado.
Company profile
Ticker
NXEN
Exchange
Website
CEO
Richard Greenberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Intiva BioPharma Inc., Kinder Holding Corp.
SEC CIK
NXEN stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
15 May 24
10-Q
2024 Q2
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
14 Feb 24
10-Q
2024 Q1
Quarterly report
14 Nov 23
10-K
2023 FY
Annual report
28 Sep 23
10-Q
2023 Q3
Quarterly report
17 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-Q
2023 Q2
Quarterly report
8 Feb 23
10-Q
2023 Q1
Quarterly report
9 Nov 22
10-K
2022 FY
Annual report
28 Sep 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.07 k | 10.07 k | 10.07 k | 10.07 k | 10.07 k | 10.07 k |
Cash burn (monthly) | (no burn) | 3.68 k | (no burn) | (no burn) | 6.98 k | 6.04 k |
Cash used (since last report) | n/a | 21.66 k | n/a | n/a | 41.12 k | 35.59 k |
Cash remaining | n/a | -11.59 k | n/a | n/a | -31.05 k | -25.52 k |
Runway (months of cash) | n/a | -3.2 | n/a | n/a | -4.4 | -4.2 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 May 24 | Richard S Greenberg | Common Stock | Grant | Acquire A | No | No | 0 | 1,000,000 | 0.00 | 7,185,193 |
23 May 24 | Evan L Wasoff | Common stock | Grant | Acquire A | No | No | 0 | 2,000,000 | 0.00 | 6,500,000 |
31 Oct 23 | Evan L Wasoff | Common stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 4,500,000 |
31 Oct 23 | Richard S Greenberg | Common Stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 6,185,193 |
25 Jul 23 | Evan L Wasoff | Common stock | Grant | Acquire A | No | No | 0 | 250,000 | 0.00 | 4,250,000 |